Transdermal clonidine for hypertensive patients.

Area of Science:

• Cardiology
• Pharmacology
• Dermatology

Background:

• Hypertension management often involves multiple daily medications.
• Oral clonidine requires frequent dosing for consistent blood pressure control.
• Hydrochlorothiazide is a commonly used diuretic for hypertension.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel transdermal clonidine system for hypertension.
• To compare blood pressure control using weekly transdermal clonidine patches versus daily oral clonidine.
• To assess plasma clonidine levels during a once-weekly transdermal application regimen.

Main Methods:

• Seventeen patients with moderate hypertension, previously controlled on oral clonidine and hydrochlorothiazide, were enrolled.
• Patients transitioned to a weekly transdermal clonidine patch system (3 mg/patch) while continuing daily hydrochlorothiazide (50 mg).
• Blood pressure was monitored, and plasma clonidine levels were measured at various time points post-patch application and during oral therapy.

Main Results:

• Fifteen out of 17 patients (88%) achieved their baseline blood pressure levels within 4-8 weeks of transdermal therapy.
• Mean blood pressure during transdermal therapy was comparable to baseline and oral therapy levels (130 +/- 10/84 +/- 6 mmHg).
• Plasma clonidine levels remained stable throughout the week after patch application, similar to trough levels during oral therapy.

Conclusions:

• Once-weekly transdermal clonidine patches effectively control blood pressure in moderately hypertensive patients.
• This novel delivery system offers a convenient alternative to daily oral clonidine dosing.
• Transdermal clonidine patches provide consistent plasma drug levels, ensuring sustained antihypertensive effects.